Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent P, Akin C, Metcalfe DD
Blood · 2017
Grade Anarrative review
Key Findings
- ●Updated WHO classification overview
- ●CD2, CD25, CD30 as aberrant MC markers
- ●Potential therapeutic targets including CD30, CD33, CD123
Referenced in (1 disease)
ID: pmid-28031180DOI: 10.1182/blood-2016-09-731893PMID: 28031180